Improvement of osteogenesis and antibacterial properties of a bioactive glass/gelatin-based scaffold using zoledronic acid and CM11 peptide
Vazifehdoust S., Shalizar-Jalali A., Nourani MR., Moosazadeh Moghaddam M., Yazdanian M.
Laboratory Study, published in Vet Res Forum (2024) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Laboratory Study
- Journal
- Vet Res Forum (2024)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 39564474
- PMCID
- PMC11571045
- DOI
- 10.30466/vrf.2024.2020333.4136
Abstract (original English)
This study aimed to investigate the effects of zoledronic acid (ZA) and antibacterial CM11 peptide on the osteoinduction and antibacterial properties of bioactive glass (BG). The bioactive glass/gelatin (BG/Gel) composite was synthesized using the sol-gel method. The 2-x minimum inhibitory concentration of the peptide and 4.00 mg mL -1 of ZA were added to the BG/Gel during fabrication. The BG/Gel composite morphological and structural characteristics and anti-bacterial activities were analyzed using Fourier transform infra-red spectroscopy, scanning electron microscopy and disk diffusion test, respectively. The release of the peptide and ZA from BG/Gel was measured using ultra-violet spectroscopy. After 14 days, the effects of the peptide/ ZA-containing BG/Gel (PZ-BG/Gel) on the growth and differentiation of mesenchymal stem cells were evaluated using 3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide, calcium and alkaline phosphatase assays, immunocytochemical staining for osteocalcin (OCN) and real-time polymerase chain reaction for OCN , type I collagen , bone morphogenetic protein 2 and Runt-related transcription factor-2 genes. The disk diffusion test showed the anti-microbial activity of the scaffold against multi-drug-resistant isolates of Pseudomonas aeruginosa and Staphylococcus aureus . Analyses showed a significantly higher level of stem cells differentiat
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.